1N7 Stock Overview
A medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nevro Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.10 |
| 52 Week High | US$20.20 |
| 52 Week Low | US$3.78 |
| Beta | 0.93 |
| 11 Month Change | -3.76% |
| 3 Month Change | -21.15% |
| 1 Year Change | -72.30% |
| 33 Year Change | -94.71% |
| 5 Year Change | -95.94% |
| Change since IPO | -79.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1N7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.8% | 0.5% | 0.2% |
| 1Y | -72.3% | -6.8% | 8.5% |
Return vs Industry: 1N7 underperformed the German Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: 1N7 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 1N7 volatility | |
|---|---|
| 1N7 Average Weekly Movement | 14.3% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1N7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1N7's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 1,215 | Kevin Thornal | nevro.com |
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands.
Nevro Corp. Fundamentals Summary
| 1N7 fundamental statistics | |
|---|---|
| Market cap | €162.65m |
| Earnings (TTM) | -€66.56m |
| Revenue (TTM) | €402.51m |
0.4x
P/S Ratio-2.4x
P/E RatioIs 1N7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1N7 income statement (TTM) | |
|---|---|
| Revenue | US$419.15m |
| Cost of Revenue | US$134.06m |
| Gross Profit | US$285.09m |
| Other Expenses | US$354.40m |
| Earnings | -US$69.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 68.02% |
| Net Profit Margin | -16.54% |
| Debt/Equity Ratio | 81.2% |
How did 1N7 perform over the long term?
See historical performance and comparison